Abstract 304
Improvement in IBDQ Scores at week 56 in the CHARM trial
Improvements from baseline
Placebo
ADA 40 mg eow
ADA 40 mg weekly
Patients (n)
26
21
28
Total IBDQ (mean change)
21.6
43.5*
46.8*
⩾16-pt IBDQ gain (%)
46
76*
86**
*p<0.05, **p<0.01, both vs placebo.